Century Therapeutics, Inc. (IPSC) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Century Therapeutics, Inc. (IPSC:NASDAQ), powered by AI.

Current Price
$2.25
Sector
Healthcare
What is the Century Therapeutics, Inc. stock price forecast?

Century Therapeutics, Inc. is currently trading at $2.25. View real-time AI analysis on Alpha Lenz.

What is Century Therapeutics, Inc. insider trading activity?

View the latest insider trading data for Century Therapeutics, Inc. on Alpha Lenz.

What is Century Therapeutics, Inc.'s P/E ratio?

View Century Therapeutics, Inc.'s valuation metrics on Alpha Lenz.

Century Therapeutics, Inc.

NASDAQ · IPSC
$2.25+0.01(+0.45%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Century Therapeutics, Inc.'s future dividend policy...
Alpha Chat Insight

Century Therapeutics, Inc.'s ROE is -6.0%. Explore profitability and growth together.

Ask for details

Company Overview

Century Therapeutics Inc. is a biotechnology company that focuses on developing innovative cell therapies for cancer treatment. The company's core mission centers around harnessing the potential of induced pluripotent stem cells (iPSCs) to create highly effective, off-the-shelf cellular therapies. By leveraging iPSCs, Century Therapeutics aims to produce uniformly engineered allogeneic cell products designed to target and eliminate cancer cells with precision. Century Therapeutics operates primarily within the healthcare and biopharmaceutical industry, specifically targeting the oncology sector. It seeks to address unmet medical needs by offering more accessible and potent therapeutic solutions compared to traditional cancer treatments. The company's research and development efforts are focused on using its technology platform to generate natural killer (NK) cells and T cells that possess enhanced tumor-fighting capabilities. In the financial market, Century Therapeutics plays a vital role in driving innovation in cancer treatment solutions. It represents a segment of biotechnology firms dedicated to advancing cellular immunotherapies, potentially transforming the landscape of cancer care and treatment. The company's work contributes to the growing field of cell therapy, highlighting the importance of biotechnological advances in modern medicine.

CEODr. Brent Pfeiffenberger M.B.A., Pharm.D.
SectorHealthcare
IndustryBiotechnology
Employees140

Company Statistics

FY 2025

Profile

N/AMarket Cap
$109.16MRevenue
0.00Shares Out
140Employees

Margins

N/AGross
8.57%EBITDA
-9.62%Operating
-8.84%Pre-Tax
-8.78%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

175.88%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-3.32%ROA
-5.98%ROE
-3.64%ROIC

Financial Health

$61.85MCash & Cash Equivalents
$2.92MNet Debt
40.75%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Century Therapeutics, Inc. (ticker: IPSC) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 140 employees.

The current price is $2.25 with a P/E ratio of -x and P/B of -x.

ROE is -5.98% and operating margin is -9.62%. Annual revenue is $109M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Century Therapeutics, Inc. (IPSC) Stock Forecast 2026 $2.25 — Price, Financials & Analyst Targets | Alpha Lenz